Management of breast cancer with bone metastases

Bone

Volumn 12, Issue SUPPL. 1, 1991, Pages

  Clavel, M ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; LOMUSTINE; METHOTREXATE; MITOMYCIN C; PREDNISOLONE; TENIPOSIDE; THIOTEPA; VINBLASTINE; VINCRISTINE;

ARTICLE; BONE METASTASIS; BREAST CANCER; FEMALE; HUMAN; SURVIVAL RATE;

AMINOGLUTETHIMIDE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; ESTROGENS; HUMAN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE 17-ACETATE; NEOPLASMS, HORMONE-DEPENDENT; PALLIATIVE CARE; SURVIVAL RATE;

EID: 0025882743     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/8756-3282(91)90060-V     Document Type: Article

References (22)

1. Metastatic breast cancer: clinical retrospective revision of 343 cases
2. Evolution du cancer du sein en phase avencee. Description et tentative d'approche du pronostic. A propos de 310 malades traitees au Centre Leon Berard
3. Combination chemotherapy of carcinoma of the breast
4. La chimiotherapie du cancer du sein en phase metastatique
5. Monthly chemotherapy (MCT) versus multiple induction chemotherapy (MICT) in non endocrine dependant metastatic breast carcinoma
6. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent treatment and continuous strategies
7. A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)
8. Natural history and course of bone metastases. A review of 429 cases
9. Diminished efficacy by reduced duration of CEF from 18 to 6 months in the treatment of metastatic breast cancer
10. Cyclophosphamide (CTx), total body irradiation (TBI) with autologous bone marrow infusion (ABM) as consolidation for inflammatory and metastatic breast cancers
11. Breast cancer modelling for prognosis and treatment
12. Chemotherapy of breast cancer: a general overview
13. A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer
14. Randomized trials in cancer and clinical review by sites
15. Induction (IND) chemotherapy (CRx) followed by maintenance (MNT) or observation (OBS) in women with metastatic breast cancer (MBC). A randomized trial of the Piedmont Oncology Association (POA)
16. Does more intensive palliative treatment improve overall survival in metastatic breast cancer patients?
17. Does current systemic therapy prolong survival in breast cancer
18. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer
19. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy
20. High-dose chemotherapy and autologous bone marrow support with emphasis on breast cancer
21. Survival of women with metastatic breast cancer at Yale from 1920 to 1980